Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program

Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program

(2016) John E. Mazuski et al.   CLINICAL INFECTIOUS DISEASES

Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study

(2016) Yehuda Carmeli et al.   LANCET INFECTIOUS DISEASES

Effects of Klebsiella pneumoniae Carbapenemase Subtypes, Extended-Spectrum β-Lactamases, and Porin Mutations on theIn VitroActivity of Ceftazidime-Avibactam against Carbapenem-Resistant K. pneumoniae

(2015) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Appropriate initial antibiotic therapy in hospitalized patients with gram-negative infections: systematic review and meta-analysis

(2015) Gowri Raman et al.   BMC INFECTIOUS DISEASES

Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options

(2015) Yoav Golan   BMC INFECTIOUS DISEASES

Urinary tract infections: epidemiology, mechanisms of infection and treatment options

(2015) Ana L. Flores-Mireles et al.   NATURE REVIEWS MICROBIOLOGY

The emerging threat of multidrug-resistant Gram-negative bacteria in urology

(2015) Hosam M. Zowawi et al.   Nature Reviews Urology

In VivoEfficacy of Humanized Exposures of Ceftazidime-Avibactam in Comparison with Ceftazidime against Contemporary Enterobacteriaceae Isolates

(2014) Shawn H. MacVane et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of a Ceftazidime-Avibactam Combination in a Murine Model of Septicemia Caused by Enterobacteriaceae Species Producing AmpC or Extended-Spectrum β-Lactamases

(2014) Premavathy Levasseur et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Bactericidal Activity, Absence of Serum Effect, and Time-Kill Kinetics of Ceftazidime-Avibactam against β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa

(2014) Tiffany R. Keepers et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Healthcare-associated urinary tract infections in hospitalized urological patients—a global perspective: results from the GPIU studies 2003–2010

(2014) Mete Cek et al.   WORLD JOURNAL OF UROLOGY

Structural Insight into Potent Broad-Spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-Lactamases

(2013) Sushmita D. Lahiri et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Contemporary Diversity of β-Lactamases among Enterobacteriaceae in the Nine U.S. Census Regions and Ceftazidime-Avibactam Activity Tested against Isolates Producing the Most Prevalent β-Lactamase Groups

(2013) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Carbapenem-resistant Enterobacteriaceae: A menace to our most vulnerable patients

(2013) F. Perez et al.   CLEVELAND CLINIC JOURNAL OF MEDICINE

Emerging resistance problems and future perspectives in pharmacotherapy for complicated urinary tract infections

(2013) Yen-Hsu Chen et al.   EXPERT OPINION ON PHARMACOTHERAPY

Health Care–Associated Infections

(2013) Eyal Zimlichman et al.   JAMA Internal Medicine

Treatment of Complicated Urinary Tract Infections With an Emphasis on Drug-Resistant Gram-Negative Uropathogens

(2013) Matthew E. Levison et al.   Current Infectious Disease Reports

Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe

(2012) R. Cantón et al.   CLINICAL MICROBIOLOGY AND INFECTION

Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study

(2012) José A. Vazquez et al.   CURRENT MEDICAL RESEARCH AND OPINION

Critical review of current definitions of urinary tract infections and proposal of an EAU/ESIU classification system

(2011) Truls E. Bjerklund Johansen et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region

(2011) Po-Ren Hsueh et al.   JOURNAL OF INFECTION

Current Concepts in Antimicrobial Therapy Against Resistant Gram-Negative Organisms: Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae, Carbapenem-Resistant Enterobacteriaceae, and Multidrug-Resistant Pseudomonas aeruginosa

(2011) Souha S. Kanj et al.   MAYO CLINIC PROCEEDINGS

The epidemiology of urinary tract infection

(2010) Betsy Foxman   Nature Reviews Urology

Cluster of bloodstream infections caused by KPC-2 carbapenemase-producing Klebsiella pneumoniae in Manhattan

(2009) Abhijeet S. Nadkarni et al.   AMERICAN JOURNAL OF INFECTION CONTROL

Urinary Bactericidal Activity of Doripenem versus That of Levofloxacin in Patients with Complicated Urinary Tract Infections or Pyelonephritis

(2009) F. M. E. Wagenlehner et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Intravenous Doripenem at 500 Milligrams versus Levofloxacin at 250 Milligrams, with an Option To Switch to Oral Therapy, for Treatment of Complicated Lower Urinary Tract Infection and Pyelonephritis

(2009) K. G. Naber et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Emergence of clonally related Klebsiella pneumoniae isolates of sequence type 258 producing plasmid-mediated KPC carbapenemase in Norway and Sweden

(2009) O. Samuelsen et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY